Roivant Sciences President & Immunovant CEO Exercises Options and Sells $7.32M in Stock Under 10b5-1 Plan

Insider Transaction Overview

On September 30, 2026, Eric Venker, President of Roivant Sciences Ltd. and CEO of Immunovant, executed an option exercise and subsequent sale of 200,000 common shares under a pre-established Rule 10b5-1 trading plan.

• Option Exercise: Exercised 200,000 stock options with an exercise price of $3.85 per share.
• Open Market Sale: Sold 200,000 common shares at a weighted average price of $36.62 per share (ranging from $36.49 to $36.76), generating gross proceeds of approximately $7,324,000.
• Net Proceeds: Pre-tax spread of approximately $32.77 per share, yielding approximately $6,554,000 above exercise costs.

Post-Transaction Holdings

Following the transactions:

• Direct Common Shares Held: 1,599,154 shares.
• Remaining Derivative Securities: 3,644,834 options to purchase common stock expiring April 19, 2032.

Strategic and Trading Significance

This transaction reflects a standard pre-scheduled exercise and liquidation of stock options. Because the sales were carried out under a Rule 10b5-1 plan adopted on March 28, 2025, the timing does not appear discretionary. Furthermore, the reporting person retains over 1.59 million directly held common shares and more than 3.64 million vested options, maintaining substantial equity exposure to Roivant Sciences.